By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Live Trading NewsLive Trading NewsLive Trading News
  • Stocks
  • Forex
  • Gold
  • KNIGHTS
  • Luxury
  • Horse Racing
  • Trade Now
Search
Reading: Sitting on a Cash Pile 12.0? BioTech Favored Over Legacy Pharma
Share
Live Trading NewsLive Trading News
  • Stocks
  • Forex
  • Gold
  • KNIGHTS
  • Luxury
  • Horse Racing
  • Trade Now
Search
  • Stocks
  • Forex
  • Gold
  • KNIGHTS
  • Luxury
  • Horse Racing
  • Trade Now
Follow US
© 2024 LiveTradingNews.com - All Rights Reserved.
Live Trading News > Blog > 2021 > Sitting on a Cash Pile 12.0? BioTech Favored Over Legacy Pharma
2021

Sitting on a Cash Pile 12.0? BioTech Favored Over Legacy Pharma

Paul Ebeling
Last updated: March 2, 2021 4:54 am
Paul Ebeling
Share
2 Min Read
SHARE

#cash #bullish #buy

$BCRX

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) brokout on 10 November at 4.08 and confirmed on 11 March at 11.98. Thus garnering an LTN Cash Pile Buy rating with a 1yr price target at 16+/share

The stock is currently trading at 11.98 within its 52 wk trading range of 1.58 – 12.90

The consensus 1 yr price objective is 13.78. Our price target is 16/share.

The Key support is at 11.17 and the resistance is light at 12.72. the majority of our Key technical indicators are Very Bullish in here.

BioCryst Pharmaceuticals, Inc., a biotech company, discovers oral and small-molecule medicines.

The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

The company has collaborations and in-license relationships with US Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.

BioCryst Pharmaceuticals, Inc. was founded in Y 1986 and is HQ’d in Durham, North Carolina.

Have a healthy day, Keep the Faith!

You Might Also Like

US Bombs Iran: Escalation and Implications

Bitcoin Dip Is Your Opportunity

Google Password Leak Update

Bitcoin’s Rise and the Future of Global Digital Markets

WW3 Will Trump Attack Iran as a Show of Strength to Russia and China? $QQQ $SPY $BTC

TAGGED:BCRXBioCrystbiotechBullishbusinessbuycashnewsresistanresistanceservicessupportTradeWebTRITWVeryBullish

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

Subscribe our newsletter for latest news around the world. Let's stay updated!

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
By Paul Ebeling
Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he is the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.   
Previous Article Wall Street’s Key Stock Analysts Research Report, All Buys
Next Article 200 billionaires were created in China last year


Latest News

De-Dollarization Is Inevitable
America Gold Headline News Most Popular Must Read Opinion Politics Shayne Heffernan USD June 21, 2025
USA Bombs Iran
America Gold Headline News Middle East Opinion Politics Shayne Heffernan Shayne Heffernan June 21, 2025
Eight Killed in Brazil Hot Air Balloon Crash
Headline News Travel June 21, 2025
Iran Rocked by 5.1-Magnitude Earthquake
Headline News June 20, 2025

Stay Connected

235.3kFollowersLike
69.1kFollowersFollow
11.6kFollowersPin
56.4kFollowersFollow
4.4kFollowersFollow
//

Stay informed with LiveTradingNews.com – your ultimate destination for timely and insightful updates on global markets, finance, and investment trends. Explore the latest news and analysis to empower your trading decisions.

Quick Link

  • About us
  • Advertise
  • Send us a tip!
  • Privacy Policy
  • Contact us

Top Categories

  • Knightsbridge Insights
  • Featured
  • Stocks
  • Shayne Heffernan
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Subscribe our newsletter for latest news around the world. Let's stay updated!

Live Trading NewsLive Trading News
Follow US
© 2025 LiveTradingNews - For The Traders, By The Traders – All Right Reserved By Knightsbridge Group
Welcome Back!

Sign in to your account

Register Lost your password?